Abstract:Alzheimer's disease (AD) is the most common age-associated neurodegenerative disorder, characterized by progressive cognitive decline, memory impairment, and structural brain changes, primarily involving Aβ plaques and neurofibrillary tangles of hyperphosphorylated tau protein. Recent research highlights the significance of smaller Aβ and Tau oligomeric aggregates (AβO and TauO, respectively) in synaptic dysfunction and disease progression. Calcineurin (CaN), a key calcium/calmodulin-dependent player in regulating synaptic function in the central nervous system (CNS) is implicated in mediating detrimental effects of AβO on synapses and memory function in AD. This study aims to investigate the specific impact of CaN on both exogenous and endogenous TauO through the acute and chronic inhibition of CaN. We previously demonstrated the protective effect against AD of the immunosuppressant CaN inhibitor, FK506, but its influence on TauO remains unclear. In this study, we explored the short-term effects of acute CaN inhibition on TauO phosphorylation and TauO-induced memory deficits and synaptic dysfunction. Mice received FK506 post-TauO intracerebroventricular injection and TauO levels and phosphorylation were assessed, examining their impact on CaN and GSK-3β. The study investigated FK506 preventive/reversal effects on TauO-induced clustering of CaN and GSK-3β. Memory and synaptic function in TauO-injected mice were evaluated with/without FK506. Chronic FK506 treatment in 3xTgAD mice explored its influence on CaN, Aβ, and Tau levels. This study underscores the significant influence of CaN inhibition on TauO and associated AD pathology, suggesting therapeutic potential in targeting CaN for addressing various aspects of AD onset and progression. These findings provide valuable insights for potential interventions in AD, emphasizing the need for further exploration of CaN-targeted strategies.

Inhibition Of Calcineurin By Infusion Of Csa Causes Hyperphosphorylation Of Tau And Is Accompanied By Abnormal Behavior In Mice

Infusion of FK506, a Specific Inhibitor of Calcineurin, Induces Potent Tau Hyperphosphorylation in Mouse Brain

Modulation of Calcineurin Activity in Mouse Brain by Chronic Oral Administration of Cyclosporine A.

Inhibition of Calcineurin with FK506 Reduces Tau Levels and Attenuates Synaptic Impairment Driven by Tau Oligomers in the Hippocampus of Male Mouse Models

Dephosphorylation of Tau Protein by Calcineurin Triturated into Neural Living Cells

Effects of cyclosporin A, FK506 and rapamycin on calcineurin phosphatase activity in mouse brain.

Alzheimer-like behavior and synaptic dysfunction in 3 × Tg-AD mice are reversed with calcineurin inhibition

Effects of Calcineurin on LTP of Rats in Vivo

Tau Accumulation Induces Synaptic Impairment and Memory Deficit by Calcineurin-Mediated Inactivation of Nuclear CaMKIV/CREB Signaling

Regulations of calcineurin B subunit and calmodulin on calcineurin A subunit with tau and its truncation mutant as substrates: Regulations of CNB and CaM on CNA with tau substrate

Inducible and Reversible Enhancement of Learning, Memory, and Long-Term Potentiation by Genetic Inhibition of Calcineurin.

Tau Binds Both Subunits of Calcineurin, and Binding is Impaired by Calmodulin

Different regulation modes of calcineurin regulatory subunit on its catalytic subunit with RII peptide and tau as substrates.

Inhibition of Calcineurin in the Prefrontal Cortex Induced Depressive-Like Behavior Through Mtor Signaling Pathway

Calcineurin inhibition prevents synaptic plasticity deficit induced by brain-derived tau oligomers

The Interaction Between Calcineurin and Α-Synuclein is Regulated by Calcium and Calmodulin.

Hippocampal CA3 Calcineurin Activity Participates in Depressive‐like Behavior in Rats

Calcium Signaling, Excitability, and Synaptic Plasticity Defects in a Mouse Model of Alzheimer's Disease.

High Level Calcineurin Activity Predisposes Neuronal Cells to Apoptosis.

Calcium Ions Stimulate the Hyperphosphorylation of Tau by Activating Microsomal Prostaglandin E Synthase 1

Cyclosporine A (CsA) prevents synaptic impairment caused by truncated tau by caspase-3